The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?

Bibliografski detalji
Glavni autor:	Hamdy, F
Format:	Journal article
Jezik:	English
Izdano:	Wiley 2017

Slični predmeti

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
od: J. Donovan, i dr.
Izdano: (2003-01-01)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
od: Hamdy, F, i dr.
Izdano: (2006)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
od: Lane, J, i dr.
Izdano: (2004)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, i dr.
Izdano: (2010)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
od: Burton, A, i dr.
Izdano: (2013)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, i dr.
Izdano: (2008)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
od: Adams, Charleen D., i dr.
Izdano: (2018)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
od: Zuccolo, L, i dr.
Izdano: (2013)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
od: Dimitropoulou, P, i dr.
Izdano: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
od: Dimitropoulou, P, i dr.
Izdano: (2011)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
od: Johnston, T, i dr.
Izdano: (2016)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
od: Catto, J, i dr.
Izdano: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
od: Catto, J, i dr.
Izdano: (2011)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
od: Er, V, i dr.
Izdano: (2017)

Development Effectiveness: What Have We Learnt?
od: Collier, P, i dr.
Izdano: (2004)

What have we learnt from SARS?
od: Weiss, R, i dr.
Izdano: (2004)

RECURRENT STROKE: WHAT HAVE WE LEARNT?
od: EM Khoo, i dr.
Izdano: (2007-01-01)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, i dr.
Izdano: (2009)

Vaginal mesh: What lessons have we learnt?
od: Dudley Robinson, i dr.
Izdano: (2020-10-01)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
od: Isaac Yi Kim
Izdano: (2023-07-01)

Exploring Online Physical Education Teaching: What Have We Done and What Have We Learnt?
od: Varanisese Tagimaucia, i dr.
Izdano: (2024-03-01)

Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt.
od: Ahmed, A, i dr.
Izdano: (2005)

Editorial: Cancer Epidemiology in China: What We Have Learnt So Far?
od: Tianhui Chen, i dr.
Izdano: (2020-02-01)

Pediatric Myocarditis: What Have We Learnt So Far?
od: Elettra Pomiato, i dr.
Izdano: (2022-05-01)

Mobile Usability in Educational Contexts: What have we learnt?
od: Agnes Kukulska-Hulme
Izdano: (2007-06-01)

Mobile Usability in Educational Contexts: What have we learnt?
od: Agnes Kukulska-Hulme
Izdano: (2007-06-01)

Twenty years of childhood blindness: what have we learnt?
od: Clare Gilbert, i dr.
Izdano: (2008-09-01)

Taking stock of the Trinitarian renaissance: What have we learnt?
od: Rian Venter
Izdano: (2019-11-01)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
od: Mills, N, i dr.
Izdano: (2003)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
od: Donovan, J, i dr.
Izdano: (2003)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
od: Wade, J, i dr.
Izdano: (2015)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
od: Lane, A, i dr.
Izdano: (2016)

What have we learnt from targeted anti-TNF therapy?
od: Feldmann, M, i dr.
Izdano: (2010)

Introduction. Emerging infections: what have we learnt from SARS?
od: Mclean, A, i dr.
Izdano: (2004)

Emerging infections: What have we learnt from SARS - Introduction
od: Mclean, A, i dr.
Izdano: (2004)

What have we learnt from the last ten years of ART?
od: W D Francois Venter
Izdano: (2014-02-01)

Epidemiology of COVID-19: What have we learnt until now?
od: Pekmezović Tatjana
Izdano: (2021-01-01)